IO Biotech, Inc.
Cash Flow Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-95.5M | $-86.1M | $-71.5M | $-67.9M | $-12.0M |
| Depreciation & Amortization | $300.0K | $200.0K | $100.0K | $0 | — |
| Depreciation | $253.0K | $215.0K | $104.0K | $2.0K | — |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $6.5M | $8.1M | $7.0M | $1.8M | $64.0K |
| Net Cash from Operating Activities | $-82.3M | $-71.7M | $-59.7M | $-40.6M | $-10.0M |
| Investing Activities | |||||
| Capital Expenditures | $44.0K | $323.0K | $690.0K | $153.0K | — |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $-44.0K | $-323.0K | $-690.0K | $-153.0K | — |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | — | $71.9M | — | $253.0M | $5.1M |
| Net Change in Cash | — | — | — | — | — |
| Free Cash Flow | $-82.4M | $-72.1M | $-60.4M | $-40.8M | — |